Xi'an International Medical Investment (000516) Fundamentals 2026 — Revenue Analysis | SniperIQ
Xi'an International Medical Investment (000516) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥9.3B, trading at ¥4.15 on the SHZ. This SniperIQ fundamentals page covers Xi'an International Medical Investment's valuation, profitability (net margin -6.3%), revenue (¥4.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Xi'an International Medical Investment's market cap?
Xi'an International Medical Investment (000516) has a market capitalization of approximately ¥9.3B, trading at ¥4.15 on the SHZ. Market cap moves with the live share price.
What is Xi'an International Medical Investment's P/E ratio?
Xi'an International Medical Investment's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Xi'an International Medical Investment?
Xi'an International Medical Investment runs a net profit margin of -6.3%, a gross margin of 9.2%, and an operating margin of -7.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Xi'an International Medical Investment generate?
Xi'an International Medical Investment reported revenue of ¥4.1B for fiscal year 2025, with net income of -¥313M and earnings per share (EPS) of -0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Xi'an International Medical Investment pay a dividend?
Xi'an International Medical Investment does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Xi'an International Medical Investment financially healthy?
Xi'an International Medical Investment carries a debt-to-equity ratio of 0.99x and a current ratio of 0.25x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Xi'an International Medical Investment a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Xi'an International Medical Investment (000516) the key facts are: market cap ¥9.3B, revenue ¥4.1B, 52-week range 3.82-6.19. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Xi'an International Medical Investment's full fundamentals live
Get Xi'an International Medical Investment's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.